Michael Batalia

Kucera is developing a pipeline of drugs that have improved efficacy and potentially improved toxicity profiles by taking advantage of the unique biological and chemical properties of its proprietary small molecule platform. Kucera has small molecules which act alone as therapeutic agents. Kucera's unique proprietary molecules can also be chemically conjugated to other small molecule drugs creating a series of carrier prodrugs. Both the prodrugs and small molecules will be classified as new chemical entities (NCEs) and will benefit from a new or an extended patent on the existing small molecule. Kucera's headquarters is in the Piedmont Triad Research Park, Winston-Salem, N.C. Kucera Pharmaceutical Co. The company was founded on June 14, 2001 and is headquartered in Winston Salem, NC.